10 Best Small Business Checking Accounts of December 2024 – Money Crashers – Go Health Pro

10 Best Small Business Checking Accounts of December 2024 – Money Crashers – Go Health Pro

Business banking is a little different from consumer banking. Our master list of the best online banks around is surprisingly short on business checking accounts with no monthly maintenance fees, minimum balance requirements, or monthly transaction limits. Also, most business bank accounts impose transaction limits and demand hefty minimum balances to waive high monthly maintenance … Read more

Zacks Small Cap Research – SWP.TO: Industry Outlook Shows Expected Catalysts for Swiss Water Growth Continuing – Go Health Pro

Zacks Small Cap Research – SWP.TO: Industry Outlook Shows Expected Catalysts for Swiss Water Growth Continuing – Go Health Pro

By M. Marin OTC:SWSSF | TSX:SWP.TO READ THE FULL SWP.TO RESEARCH REPORT Rising consumption of ‘decaf’ & specialty coffees important are growth drivers that are expected to continue… British Columbia-based Swiss Water Decaffeinated Coffee Inc. (OTC:SWSSF) (TSX:SWP.TO) is a leading specialty coffee company and premium green coffee decaffeinator focused on producing chemical-free decaffeinated coffee. The … Read more

Zacks Small Cap Research – LEXX: Phase I Start Imminent – Go Health Pro

Zacks Small Cap Research – LEXX: Phase I Start Imminent – Go Health Pro

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal third 2024 results along with program updates, progress in its GLP-1 trials, a capital raise and final preparations for the Phase Ib trial evaluating DehydraTECH in obese patients. Several new patents were granted bringing the total to 43. … Read more

Zacks Small Cap Research – ORMP: Preparations for New Phase 3 Trial Advance, While ORMP Leverages Balance Sheet Through Recent Agreements – Go Health Pro

Zacks Small Cap Research – ORMP: Preparations for New Phase 3 Trial Advance, While ORMP Leverages Balance Sheet Through Recent Agreements – Go Health Pro

By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Planning Phase 3 Oral Insulin study under revised protocol, new CRO agreement in place Oramed Pharmaceuticals (NASDAQ:ORMP) has pivoted its clinical R&D focus to prioritize studying ORMD 0801 for subpopulations of patients with pooled specific parameters who responded well to oral insulin in its prior … Read more

x